Last five years | All
2018 2017 2016 2015
| 2018 Original Articles | |||
| o | Maier J, Mayer FP, Luethi D, Holy M, Jaentsch K, Reither H, Hirtler L, Hoener MC, Liechti ME, Pifl C, Brandt SD, Sitte HH (2018) The psychostimulant (±)-cis-4,4′-dimethylaminorex (4,4′-DMAR) interacts with human plasmalemmal and vesicular monoamine transporters Neuropharmacology, 138: 282-291 | ||
| 2017 Original Articles | |||
| o | Tong J, Rathitharan G, Meyer JH, Furukawa Y, Ang LC, Boileau I, Guttman M, Hornykiewicz O, Kish SJ (2017) Brain monoamine oxidase B and A in human parkinsonian dopamine deficiency disorders Brain, 140: 2460-2474 | ||
| o | Pifl C, Reither H, Lopez-Gonzalez del Rey N, Cavada C, Obeso JA, Blesa J (2017) Early paradoxical increase of dopamine: A neurochemical study of olfactory bulb in asymptomatic and symptomatic MPTP treated monkeys Front Neuroanat, 11: 46 | ||
| o | Rivetti di Val Cervo P, Romanov RA, Spigolon G, Masini D, Martín-Montañez E, Toledo EM, La Manno G, Feyder M, Pifl C, Ng YH, Sánchez SP, Linnarsson S, Wernig M, Harkany T, Fisone G, Arenas E (2017) Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson's disease model Nat Biotechnol, 35: 444-452 | ||
| o | Hornykiewicz O (2017) L-DOPA J Parkinson Dis, 7 (s1): S3-S10 | ||
| 2016 Original Articles | |||
| o | Furukawa Y, Rajput A, Tong J, Tomizawa Y, Hornykiewicz O, Kish S (2016) A marked contrast between serotonergic and dopaminergic changes in dopa-responsive dystonia: Table Neurology, 87 (10): 1060-1061 | ||
| o | Peneder T, Bauer J, Pifl C (2016) Apoptosis-inducing factor in nigral dopamine neurons: Higher levels in primates than in mice Movement Disorders, 31: 1729-1733 | ||
| o | Sitte HH, Pifl C, Rajput AH, Hörtnagl H, Tong J, Lloyd GK, Kish SJ, Hornykiewicz O (2016) Dopamine and noradrenaline, but not serotonin, in the human claustrum are greatly reduced in patients with Parkinson's disease: possible functional implications Eur J Neurosci, 45: 192-197 | ||
| o | Pifl C (2016) Problems with traffic ahead: Synaptic vesicles in Parkinson's disease Movement Disorders, 31: 1480 | ||
| o | Berger ML (2016) Soaping the NMDA receptor: Various types of detergents influence differently [³H]MK-801 binding to rat brain membranes Biochim Biophys Acta, 1858: 116-122 | ||
| 2015 Original Articles | |||
| o | Hornykiewicz O (2015) 50 years of levodopa Movement Disorders, 30: 1008 | ||
| o | Berger ML, Rebernik P (2015) Differential influence of 7 cations on 16 non-competitive NMDA receptor blockers Bioorg Med Chem Lett, 25 (19): 4131-4135 | Article (PDF) || Weblink | | ||
| o | Ramerstorfer J, Foppa V, Thiery H, Hermange P, Janody S, Berger M, Dodd R, Sieghart W (2015) GABAA Receptor Subtype-Selectivity of Novel Bicuculline Derivates Curr Med Chem, 22: 771-780 | ||
| o | Tong J, Ang LC, Williams B, Furukawa Y, Fitzmaurice P, Guttman M, Boileau I, Hornykiewicz O, Kish SJ (2015) Low levels of astroglial markers in Parkinson's disease: relationship to alpha-synuclein accumulation Neurobiol Dis, 82: 243-253 | ||
| o | Berger M, Maciejewska D, Vanden Eynde JJ, Mottamal M, Zabinski J, Kazmierczak P, Rezler M, Jarak I, Piantanida I, Karminski-Zamola G, Mayence A, Rebernik P, Kumar A, Ismail MA, Boykin DW, Huang TL (2015) Pentamidine analogs as iInhibitors of [3H]MK-801 and [3H]ifenprodil binding to rat brain NMDA receptors Bioorg Med Chem, 23 (15): 4489-4500 Article (PDF): 1 2 || Weblink | | ||
| o | Hnat J, Berger ML (2015) Radioligand kinetics at the NMDA receptor channel revisited: an active part by Na+ and Tris Neurotransmitter, 2: e 945 | ||
| o | Karabacak Y, Sase S, Aher YD, Sase A, Saroja SR, Cicvaric A, Höger H, Berger M, Bakulev V, Sitte HH, Leban J, Monje FJ, Lubec G (2015) The effect of modafinil on the rat dopamine transporter and dopamine receptors D1-D3 paralleling cognitive enhancement in the radial arm maze Front Behav Neurosci, Epub August 2015: | ||
| o | Pifl C, Reither H, Hornykiewicz O (2015) The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter Eur J Pharmacol, 755: 119-126 | Article (PDF) | | ||
